ATE525093T1 - Modelle für die bewertung von impfstoffen - Google Patents

Modelle für die bewertung von impfstoffen

Info

Publication number
ATE525093T1
ATE525093T1 AT07872536T AT07872536T ATE525093T1 AT E525093 T1 ATE525093 T1 AT E525093T1 AT 07872536 T AT07872536 T AT 07872536T AT 07872536 T AT07872536 T AT 07872536T AT E525093 T1 ATE525093 T1 AT E525093T1
Authority
AT
Austria
Prior art keywords
models
vaccine evaluation
vaccine
evaluation
population
Prior art date
Application number
AT07872536T
Other languages
English (en)
Inventor
John Tew
Shikh Mohey El
Inderpal Singh
Eric Mishkin
Donald Drake
Haifeng Song
William Warren
Original Assignee
Sanofi Pasteur Vaxdesign Corp
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Vaxdesign Corp, Univ Virginia Commonwealth filed Critical Sanofi Pasteur Vaxdesign Corp
Application granted granted Critical
Publication of ATE525093T1 publication Critical patent/ATE525093T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT07872536T 2006-06-27 2007-06-27 Modelle für die bewertung von impfstoffen ATE525093T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81663706P 2006-06-27 2006-06-27
PCT/US2007/014826 WO2008094178A2 (en) 2006-06-27 2007-06-27 Models for vaccine assessment

Publications (1)

Publication Number Publication Date
ATE525093T1 true ATE525093T1 (de) 2011-10-15

Family

ID=39674632

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07872536T ATE525093T1 (de) 2006-06-27 2007-06-27 Modelle für die bewertung von impfstoffen

Country Status (6)

Country Link
US (2) US7709257B2 (de)
EP (3) EP2409714A1 (de)
AT (1) ATE525093T1 (de)
AU (1) AU2007345747A1 (de)
CA (1) CA2655344C (de)
WO (1) WO2008094178A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7785883B2 (en) * 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US8071373B2 (en) 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US8298824B2 (en) 2004-04-28 2012-10-30 Sanofi Pasteur Vaxdesign Corporation Methods of evaluating a test agent in a diseased cell model
US7709256B2 (en) 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US7855074B2 (en) 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
AU2006331504A1 (en) 2005-12-21 2007-07-05 Vaxdesign Corporation In vitro germinal centers
ATE531793T1 (de) * 2005-12-21 2011-11-15 Sanofi Pasteur Vaxdesign Corp Eine poröse membran gerät, das die differenzierung von monozyten in dendritische zellen fördert
EP2409714A1 (de) 2006-06-27 2012-01-25 Sanofi Pasteur VaxDesign Corporation Modelle für die Bewertung von Impfstoffen
WO2009048661A1 (en) 2007-07-16 2009-04-16 Vaxdesign Corporation Artificial tissue constructs comprising alveolar cells and methods for using the same
US20090328240A1 (en) * 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
WO2011066221A1 (en) * 2009-11-24 2011-06-03 International Aids Vaccine Initiative Immunogen prioritization for vaccine design
EP2422618A1 (de) * 2010-08-27 2012-02-29 Technologie Integrale Ltd. Tiermodell zur Beurteilung der Wirksamkeit eines HIV-Impfstoffs
BR112014006390A2 (pt) 2011-09-19 2017-03-28 Kymab Ltd anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013134464A1 (en) * 2012-03-07 2013-09-12 Children's Medical Center Corporation Tissue constructs and uses thereof
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5160490A (en) * 1986-04-18 1992-11-03 Marrow-Tech Incorporated Three-dimensional cell and tissue culture apparatus
US5032508A (en) 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5720937A (en) * 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5188959A (en) * 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
US5695996A (en) * 1994-09-23 1997-12-09 The United States Of America As Represented By The Department Of Health And Human Services Artificial organ culture system
US6479258B1 (en) * 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US5739001A (en) * 1996-10-29 1998-04-14 E. I. Du Pont De Nemours And Company Solid phase cell-based assay
US6177282B1 (en) * 1997-08-12 2001-01-23 Mcintyre John A. Antigens embedded in thermoplastic
EP1015558A1 (de) 1997-09-25 2000-07-05 Cytomatrix, LLC Verfahren und vorrichtungen zur langzeitkultur der hämatopoietischen vorläuferzellen
DE69840739D1 (de) * 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
EP1068298A1 (de) 1998-02-27 2001-01-17 Anticancer, Inc. In vitro model für virusinfektion und immune antwort
AU2848099A (en) 1998-03-25 1999-10-18 Gert Blankenstein Micro system and method for field manipulation of particules
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US20020155108A1 (en) * 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
ES2315244T3 (es) 1999-11-12 2009-04-01 Fibrogen, Inc. Gelatina recombinante en vacunas.
AU1778001A (en) * 1999-11-17 2001-05-30 University Of Rochester Human ex vivo immune system
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6541225B1 (en) * 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
WO2002062971A1 (en) * 2001-02-07 2002-08-15 Korea Atomic Energy Research Institute Method of isolating epithelial cells, method of preconditioning cells, and methods of preparing bioartificial skin and dermis with the epithelial cells or the preconditioned cells
WO2003026712A1 (en) 2001-09-25 2003-04-03 Japan Science And Technology Agency Method of preparing basement membrane, method of constructing basement membrane specimen, reconstituted artificial tissue using the basement membrane specimen and process for producing the same
WO2003041568A2 (en) 2001-11-15 2003-05-22 University Of Medicine & Dentistry Of New Jersey A three-dimensional matrix for producing living tissue equivalents
FR2833271B1 (fr) 2001-12-10 2004-09-17 Coletica Production de cellules dendritiques in vitro a partir de monocytes cd14+, pour notamment la realisation de modeles cellulaires et/ou tissulaires en suspension, en monocouches et tridimentionnels; utilisation de ces modeles
GB0130789D0 (en) * 2001-12-21 2002-02-06 King S College London Application of spores
EP1490088A4 (de) * 2002-03-18 2006-02-15 Sciperio Inc Dentritische zellknoten
AU2003226067A1 (en) * 2002-04-11 2003-10-27 Cyclex, Inc. Method for monitoring the immune response and predicting clinical outcomes in transplant recipients
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US20050191743A1 (en) * 2002-10-03 2005-09-01 Wu J.H. D. Three-dimensional peripheral lymphoid organ cell cultures
US20040109876A1 (en) * 2002-11-25 2004-06-10 Kureha Chemical Industry Co., Ltd. Vaccine composition, HIV-infection suppression factor and method for the vaccination against HIV
EP1479760A1 (de) 2003-05-19 2004-11-24 ProBioGen AG Künstliches Immunorgan
US8071373B2 (en) * 2004-04-28 2011-12-06 Sanofi Pasteur Vaxdesign Corp. Co-culture lymphoid tissue equivalent (LTE) for an artificial immune system (AIS)
US20060275270A1 (en) * 2004-04-28 2006-12-07 Warren William L In vitro mucosal tissue equivalent
US7771999B2 (en) * 2004-04-28 2010-08-10 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US7855074B2 (en) * 2004-04-28 2010-12-21 Vaxdesign Corp. Artificial immune system: methods for making and use
US7785883B2 (en) * 2004-04-28 2010-08-31 Vax Design Corp. Automatable artificial immune system (AIS)
JP5795699B2 (ja) * 2004-04-28 2015-10-14 サノフィ パスツール ヴァックスデザイン コーポレーション 人工免疫システム：作製および使用方法
US7709256B2 (en) * 2004-04-28 2010-05-04 Vaxdesign Corp. Disease model incorporation into an artificial immune system (AIS)
US8030070B2 (en) * 2004-04-28 2011-10-04 Sanofi Pasteur Vaxdesign Corp. Artificial lymphoid tissue equivalent
US7785806B2 (en) * 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
US20070141552A1 (en) * 2004-04-28 2007-06-21 Warren William L Automatable artificial immune system (AIS)
AU2005255458B2 (en) * 2004-06-09 2007-11-15 Syncada Llc Transaction processing with core and distributor processor implementations
WO2007069755A1 (ja) 2005-12-12 2007-06-21 Riken 人工リンパ節を用いた効率的な抗原特異的ハイブリドーマの作成法
ATE531793T1 (de) * 2005-12-21 2011-11-15 Sanofi Pasteur Vaxdesign Corp Eine poröse membran gerät, das die differenzierung von monozyten in dendritische zellen fördert
AU2006331504A1 (en) * 2005-12-21 2007-07-05 Vaxdesign Corporation In vitro germinal centers
EP2409714A1 (de) 2006-06-27 2012-01-25 Sanofi Pasteur VaxDesign Corporation Modelle für die Bewertung von Impfstoffen
US20090104221A1 (en) * 2007-07-06 2009-04-23 Vaxdesign Corporation Rapid generation of t cell-independent antibody responses to t cell-dependent antigens

Also Published As

Publication number Publication date
WO2008094178A3 (en) 2009-02-12
US7709257B2 (en) 2010-05-04
EP2409714A1 (de) 2012-01-25
EP2043695A2 (de) 2009-04-08
AU2007345747A1 (en) 2008-08-07
EP2043695B8 (de) 2012-02-29
WO2008094178A9 (en) 2008-10-02
CA2655344C (en) 2016-09-13
US20100287630A1 (en) 2010-11-11
CA2655344A1 (en) 2008-08-07
WO2008094178A2 (en) 2008-08-07
US20080008653A1 (en) 2008-01-10
EP2043695B1 (de) 2011-09-21
EP2409715A1 (de) 2012-01-25

Similar Documents

Publication Publication Date Title
ATE525093T1 (de) Modelle für die bewertung von impfstoffen
BRPI0710123A2 (pt) Previsão de heterose e outros traços por análise de transcriptoma.
DE60334325D1 (de) Brandüberwachungssystem für aufzug
DE602006010967D1 (de) Reise-Verknüpfungsidentifikationssystem
EP1954184A4 (de) Überwachung der menschlichen gesundheit auf residuum-basis
DE602006019915D1 (de) Isoxazoline für die bekämpfung von wirbellosen schädlingen
FI20055581L (fi) Erotusmenetelmä
DE602004021987D1 (de) Vorrichtung zum Ölabscheiden für einen Kühlmittelkompressor
DE602004001247D1 (de) Initiator für die Photopolymerisation
EP1792864A4 (de) Aufzugsvorrichtung
ITGE20040108A1 (it) Maschera subacquea e metodo per la sua fabbricazione.
DE602006008568D1 (de) Vorrichtung zur Unterscheidung von Münzwerten
EP1959431A4 (de) Skalierbare codierungsvorrichtung und skalierbares codierungsverfahren
ATE401789T1 (de) Vorrichtung
EP1956978A4 (de) Phantom für die diffusions-tensor-darstellung
DE602006009513D1 (de) Verwendung von phenylsemicarbazonen für die saatgutbeizung
DE602005010032D1 (de) Lese-/Schreibeinrichtung für einen analytischenTest
EP1934955A4 (de) Beleuchtetes zeichen
DK1894169T3 (da) Identifikationskort
ATE364216T1 (de) Wechselrahmen für plakate
EP1860050A4 (de) Eingangs-/ausgangsvorrichtung für aufzug
EP1902994A4 (de) Aufzugsvorrichtung
ATE463562T1 (de) Lp-pla2-aktivitätstest mit hohem durchsatz
DE502005010620D1 (de) Obergurtquerschnitt für Kranteleskopteile
DE102005040056B8 (de) Vorrichtung zum optischen Lesen von Informationen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties